• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Regulatory

Incannex announces completion of pre-IND meeting with FDA regarding IHL-216A inhaled CBD/isoflurane

Australian cannabinoid developer Incannex Healthcare said that its pre-IND meeting with the FDA regarding its IHL-216A inhaled CBD/isoflurane for the treatment of traumatic brain injury was "constructive." In June 2021, Incannex signed an agreement with inhalation CDMO Vectura for preclinical development services for IHL-216A. The company said at that time that … [Read more...] about Incannex announces completion of pre-IND meeting with FDA regarding IHL-216A inhaled CBD/isoflurane

Harm Reduction Therapeutics initiates rolling NDA submission for RiVive intranasal naloxone

Harm Reduction Therapeutics announced that it has made an initial filing for a rolling review of its NDA for RiVive naloxone nasal spray, an OTC product for the treatment of opioid overdose. In August 2022, the company announced that it had received Fast Track designation for RiVive (HRT001) and had signed a commercial supply agreement. The company said that it is … [Read more...] about Harm Reduction Therapeutics initiates rolling NDA submission for RiVive intranasal naloxone

Health Canada approves Ryaltris nasal spray for the treatment of seasonal allergic rhinitis

According to Bausch Health and Glenmark, Health Canada has approved Ryaltris olopatadine / mometasone furoate nasal spray for the treatment of seasonal allergic rhinitis in people aged 6 and older. Bausch Health acquired the Canadian rights to Ryaltris in March 2021. Ryaltris has been approved in Australia since December 2019, in Europe since April 2021 and in the US … [Read more...] about Health Canada approves Ryaltris nasal spray for the treatment of seasonal allergic rhinitis

China okays emergency use of CanSinoBio’s Convidecia Air inhaled COVID-19 vaccine

According to CanSino Biologics, China's National Medical Products Administration (NMPA) has approved the company's Convidecia Air nebulized COVID-19 vaccine as a booster dose. In December 2021, CanSino Bio announced a deal with Aerogen for the use of Aerogen vibrating mesh nebulizers for delivery of the adenovirus vector vaccine. … [Read more...] about China okays emergency use of CanSinoBio’s Convidecia Air inhaled COVID-19 vaccine

India clears Bharat Biotech’s iNCOVACC intranasal COVID-19 vaccine for emergency use

According to Bharat Biotech, Indian regulators have cleared its iNCOVACC (BBV154) intranasal vaccine against COVID-19 for use in adults aged 18 and older under a Restricted Use in Emergency Situation. Following the approval, Bharat Bio said, "the product will be launched and available for use in due course of time." Bharat Bio announced in September 2020 that it … [Read more...] about India clears Bharat Biotech’s iNCOVACC intranasal COVID-19 vaccine for emergency use

PADAC schedules meeting to discuss Avillion’s NDA for PT027 albuterol / budesonide MDI 

The FDA has published notice of an online meeting of the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to take place on November 8, 2022 for the purpose of discussing Avillion and AstraZeneca's NDA (214070) for PT027 albuterol / budesonide MDI for the treatment of asthma in patients aged 4 and older. The agency accepted the NDA in May 2022. According to the … [Read more...] about PADAC schedules meeting to discuss Avillion’s NDA for PT027 albuterol / budesonide MDI 

Court rules that Liquidia’s Yutrepia treprostinil DPI would infringe United Therapeutics patents covering Tyvaso

The United States District Court for the District of Delaware has ruled that Liquidia's Yutrepia treprostinil DPI would infringe claims contained in US patents 9,593,066 and 10,716,793, which cover United Therapeutics' Tyvaso inhaled treprostinil; however, the judge found that the claims in the '066 patent that would be infringed are invalid and the sole valid claim … [Read more...] about Court rules that Liquidia’s Yutrepia treprostinil DPI would infringe United Therapeutics patents covering Tyvaso

Lupin’s Lutio tiotropium bromide DPI approved for the treatment of COPD in the UK

According to Lupin, the MHRA has approved company's Lutio tiotropium bromide inhalation powder, a generic version of Boehringer Ingelheim's Spiriva Handihaler. The approval is the second for a Lupin OINDP in the UK; the MHRA approved the company's Luforbec beclometasone / formoterol MDI for the treatment of asthma and COPD, a generic of Chiesi's Fostair, in June 2021, … [Read more...] about Lupin’s Lutio tiotropium bromide DPI approved for the treatment of COPD in the UK

Adherium submits 510(k) for Hailie sensor use with Teva MDIs

Adherium has submitted a 510(k) application for use of its next generation Hailie inhaler monitoring sensor with Teva's ProAir albuterol MDI and its generic albuterol HFA MDI, the company said. Recently, the company filed a 510(k) submission for use of the Hailie sensor with GSK's Ventolin, Advair, and Flovent MDIs, and the FDA cleared the Hailie sensor for use with … [Read more...] about Adherium submits 510(k) for Hailie sensor use with Teva MDIs

Savara’s molgramostim for aPAP gets PIM designation from the MHRA

According to Savara, the MHRA has granted Promising Innovative Medicine (PIM) designation to the company's molgramostim inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The PIM designation indicates that the product could be eligible for the UK's early access to … [Read more...] about Savara’s molgramostim for aPAP gets PIM designation from the MHRA

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Interim pages omitted …
  • Page 98
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Intertek banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews